{
    "info": {
        "nct_id": "NCT06844383",
        "official_title": "A Randomized Open-label Phase 2 Study of TALazoparib with or Without ENzaluTamide in Patients with Metastatic Castration-Resistant Prostate Cancer and HRR Mutations After Progression on Abiraterone Acetate",
        "inclusion_criteria": "Inclusion Criteria\n\n• Willing and able to provide, or have a legally authorized representative provide, written informed consent and privacy authorization for the release of personal health information. A signed informed consent must be obtained before screening procedures are performed.\n\nNOTE: Privacy authorization may be either included in the informed consent or obtained separately.\n\n* Participants ≥ 18 years of age.\n* Are willing to be randomized into either study arm and adhere to the study protocol.\n* Ability to swallow study capsules and/or tablets whole.\n* Are willing to remain on study treatment and to continue undergoing study imaging despite PSA progression unless clinically deteriorating.\n* Histological or cytological proof of adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features.\n* Presence of a pathogenic homologous recombination repair mutation in at least one of the following genes on tumor tissue or circulating tumor DNA testing: BRCA1, BRCA2, ATM (limited to 15% of enrolled participants), CDK12, CHEK2, PALB2, MLH1, NBN, ATR, FANCA, MRE11A, RAD51C. Assessment of HRR mutation status by germline or somatic testing. All testing must be per Clinical Laboratory Improvement Amendments (CLIA)-certified assay and may have occurred at any time prior to or at screening (not required to be completed within the screening window).\n* Metastatic castration-resistant prostate cancer (mCRPC) as demonstrated by one of the following:\n\n  * Metastatic disease documented by conventional imaging: computed tomography (CT)/magnetic resonance imaging (MRI) chest/abdomen/pelvis and bone scan are required to be performed, but metastases do not need to be seen on both modalities. Measurable disease is not required.\n  * Unequivocal prostate-specific membrane antigen (PSMA) positron emission tomography (PET) only defined metastatic disease with negative conventional imaging. PSMA PET imaging is not required to be performed, but may be used to document metastases when relevant.\n* Received prior abiraterone acetate with prednisone for mHSPC or locally advanced disease and on which progressed via a minimum of 2 rising PSA levels with a minimum of a 1-week interval between each determination or radiographic progression by any form of imaging.\n* Progressive disease at start of treatment and in the setting of medical or surgical castration as defined by 1 or more of the following 4 criteria:\n\n  * PSA progression defined as 2 rising PSA levels, above an initial reference value, taken with a minimum of a 1-week interval. If PSA rise is the only indication of progression at start of study treatment, a minimum PSA of 1.0 ng/mL is required and all measured PSA values have to be considered to make a determination of progression.\n  * Soft tissue disease progression as defined by RECIST 1.1.\n  * Bone disease progression defined by PCWG3 with 2 or more new metastatic bone lesions on a whole-body radionuclide bone scan.\n  * Appearance of newly identified, convincingly positive lesions consistent with metastatic prostate cancer on PSMA PET.\n* Surgically or medically castrated, with testosterone levels of <50 ng/dL. If the participant is medically castrated, continuous dosing with a gonadotropin-releasing hormone agonist or antagonist must be demonstrated by testosterone level of <50 ng/dL and planned to continue throughout study participation.\n* Eastern Cooperative Oncology Group (ECOG) status of ≤1 (Appendix A: Performance Status Criteria).\n* Normal organ function with acceptable initial laboratory values within 14 days of treatment start:\n\n  * Absolute neutrophil count ≥ 1,500/µl\n  * Hemoglobin ≥ 9g/dl\n  * Platelet count ≥ 100,000/µl\n  * Creatinine ≤ 1.5 x the institutional upper limit of normal (ULN)\n  * Potassium ≥ 3.5 mmol/L (within institutional normal range)\n  * Bilirubin ≤ 1.3 x ULN (unless documented Gilbert's disease)\n  * Serum glutamic oxaloacetic transaminase/aspartate transaminase (AST) ≤ 2.5 x ULN\n  * Serum glutamic pyruvic transaminase/ alanine transaminase (ALT) ≤ 2.5 x ULN\n* Participants must agree to use a medically acceptable method of birth control (e.g., spermicide in conjunction with a barrier such as a condom) or sexual abstinence for the duration of the study, including 4 months after the last dose of study drug. Sperm donation is prohibited during the study and for 4 months after the last dose of study drug. Female partners must use hormonal or barrier contraception unless postmenopausal or abstinent.\n\nExclusion Criteria\n\n* Any other active malignancy at time of first dose of study treatment or diagnosis of another malignancy within 3 years prior to first dose of study treatment that requires active treatment, except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer or superficial bladder cancer.\n* Prior treatment for metastatic or non-metastatic CRPC with an ARPI other than abiraterone acetate with prednisone for ≥ 12 weeks. Prior treatment with abiraterone acetate with prednisone in the mHSPC or locally advanced setting is not exclusionary.\n* Participants who received chemotherapy for castration-sensitive prostate cancer are still eligible provided chemotherapy was completed >6 months prior to start of study treatment.\n* Use of investigational agents for the treatment of prostate cancer within 4 weeks of start of study treatment.\n* Prior treatment with a PARP inhibitor.\n* Concurrent treatment with crizotinib.\n* Prior platinum-based chemotherapy for the treatment of prostate cancer.\n* Current or planned use of potent P-gp inhibitors within 7 days prior to randomization. The P-gp inhibitors include: amiodarone, carvedilol, clarithromycin, cobicistat, dronedarone, erythromycin, glecaprevir/pibrentasvir, indinavir, itraconazole, ketoconazole, lapatinib, lopinavir, propafenone, quinidine, ranolazine, ritonavir, saquinavir, sofosbuvir/velpatasvir/voxilaprevir, telaprevir, tipranavir, valspodar, and verapamil.\n* Current use of strong cytochrome P450 2C8 (CYP2C8) inhibitors (e.g., clopidogrel, gemfibrozil) and inducers (e.g., rifampin), strong CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine and St. John's Wort), moderate CYP3A4 inducers (e.g., bosentan, efavirenz, etravirine, modafinil and nafcillin), or substrates of CYP3A4 (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus and tacrolimus), CYP2C9 (e.g., phenytoin, warfarin), or CYP2C19 (e.g., S-mephenytoin) with a narrow therapeutic index unless considered medically necessary to treat a life-threatening condition.\n* Participants treated with strong cytochrome P450 2C8 (CYP2C8) inhibitors (e.g., clopidogrel, gemfibrozil) within 7 days from randomization are not eligible.\n* Use of hormonal agents with anti-tumor activity against prostate cancer including 5-alpha reductase inhibitors, androgens (e.g., testosterone), cytoproterone acetate, progestational agents, and estrogens/diethylstilbestrol within 28 days prior to the start of study treatment.\n* Use of herbal products or alternative therapies that may decrease PSA levels or that may have hormonal anti-prostate cancer activity (e.g., saw palmetto, PC-SPES, PC-HOPE, St. John's wort, selenium supplements, grape seed extract, etc.) within 28 days of study treatment initiation or plans to initiate treatment with these products/alternative therapies during the entire duration of the study.\n* Participants receiving a blood transfusion within 14 days of randomization are not eligible.\n* History of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke, significant brain trauma). Also, history of loss of consciousness or transient ischemic attack within 12 months of randomization.\n* Medical conditions such as uncontrolled hypertension as indicated by a resting systolic blood pressure > 160 mm Hg or diastolic blood pressure > 90 mm Hg at screening, uncontrolled diabetes mellitus, and cardiac disease that would preclude participation, as determined by the investigator.\n* Untreated known or suspected brain metastases or spinal cord compression or clinically significant malignant epidural disease.\n* Use of any prohibited concomitant medications (Appendix C: Medications with the Potential for Drug-Drug Interactions) within 28 days before first dose of study treatment.\n* Grade >2 treatment-related toxicity from prior therapy except alopecia or peripheral neuropathy.\n* Known allergy to any of the compounds under investigation.\n* Any other condition which, in the opinion of the Investigator, would preclude participation in this trial.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "NOTE: Privacy authorization may be either included in the informed consent or obtained separately.",
                "criterions": [
                    {
                        "exact_snippets": "Privacy authorization may be either included in the informed consent or obtained separately.",
                        "criterion": "privacy authorization",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Privacy authorization may be either included in the informed consent or obtained separately.",
                        "criterion": "privacy authorization",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must be MALE",
                "criterions": [
                    {
                        "exact_snippets": "Must be MALE",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Must be MALE",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Use of any prohibited concomitant medications (Appendix C: Medications with the Potential for Drug-Drug Interactions) within 28 days before first dose of study treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Use of any prohibited concomitant medications (Appendix C: Medications with the Potential for Drug-Drug Interactions) within 28 days before first dose of study treatment.",
                        "criterion": "prohibited concomitant medication use",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Use of any prohibited concomitant medications (Appendix C: Medications with the Potential for Drug-Drug Interactions) within 28 days before first dose of study treatment.",
                        "criterion": "prohibited concomitant medication use",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days before first dose of study treatment"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Use of any prohibited concomitant medications (Appendix C: Medications with the Potential for Drug-Drug Interactions) within 28 days before first dose of study treatment.",
                        "criterion": "prohibited concomitant medication use",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Use of any prohibited concomitant medications (Appendix C: Medications with the Potential for Drug-Drug Interactions) within 28 days before first dose of study treatment.",
                        "criterion": "prohibited concomitant medication use",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days before first dose of study treatment"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Use of investigational agents for the treatment of prostate cancer within 4 weeks of start of study treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Use of investigational agents for the treatment of prostate cancer within 4 weeks of start of study treatment.",
                        "criterion": "use of investigational agents for the treatment of prostate cancer",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Use of investigational agents for the treatment of prostate cancer within 4 weeks of start of study treatment.",
                        "criterion": "use of investigational agents for the treatment of prostate cancer",
                        "requirement": {
                            "requirement_type": "timing_context",
                            "expected_value": "prior to start of study treatment"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Use of investigational agents for the treatment of prostate cancer within 4 weeks of start of study treatment.",
                        "criterion": "use of investigational agents for the treatment of prostate cancer",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Use of investigational agents for the treatment of prostate cancer within 4 weeks of start of study treatment.",
                        "criterion": "use of investigational agents for the treatment of prostate cancer",
                        "requirement": {
                            "requirement_type": "timing_context",
                            "expected_value": "prior to start of study treatment"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Normal organ function with acceptable initial laboratory values within 14 days of treatment start:",
                "criterions": [
                    {
                        "exact_snippets": "Normal organ function",
                        "criterion": "organ function",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "normal"
                        }
                    },
                    {
                        "exact_snippets": "acceptable initial laboratory values within 14 days of treatment start",
                        "criterion": "initial laboratory values",
                        "requirement": {
                            "requirement_type": "acceptability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "acceptable initial laboratory values within 14 days of treatment start",
                        "criterion": "initial laboratory values",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "within 14 days of treatment start"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Normal organ function",
                        "criterion": "organ function",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "normal"
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "acceptable initial laboratory values within 14 days of treatment start",
                                "criterion": "initial laboratory values",
                                "requirement": {
                                    "requirement_type": "acceptability",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "acceptable initial laboratory values within 14 days of treatment start",
                                "criterion": "initial laboratory values",
                                "requirement": {
                                    "requirement_type": "timing",
                                    "expected_value": "within 14 days of treatment start"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Appearance of newly identified, convincingly positive lesions consistent with metastatic prostate cancer on PSMA PET.",
                "criterions": [
                    {
                        "exact_snippets": "Appearance of newly identified, convincingly positive lesions",
                        "criterion": "lesions",
                        "requirement": {
                            "requirement_type": "appearance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Appearance of newly identified, convincingly positive lesions",
                        "criterion": "lesions",
                        "requirement": {
                            "requirement_type": "identification_status",
                            "expected_value": "newly identified"
                        }
                    },
                    {
                        "exact_snippets": "Appearance of newly identified, convincingly positive lesions",
                        "criterion": "lesions",
                        "requirement": {
                            "requirement_type": "positivity",
                            "expected_value": "convincingly positive"
                        }
                    },
                    {
                        "exact_snippets": "lesions consistent with metastatic prostate cancer",
                        "criterion": "lesion consistency with metastatic prostate cancer",
                        "requirement": {
                            "requirement_type": "consistency",
                            "expected_value": "metastatic prostate cancer"
                        }
                    },
                    {
                        "exact_snippets": "on PSMA PET",
                        "criterion": "lesion detection modality",
                        "requirement": {
                            "requirement_type": "detection modality",
                            "expected_value": "PSMA PET"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Appearance of newly identified, convincingly positive lesions",
                        "criterion": "lesions",
                        "requirement": {
                            "requirement_type": "appearance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Appearance of newly identified, convincingly positive lesions",
                        "criterion": "lesions",
                        "requirement": {
                            "requirement_type": "identification_status",
                            "expected_value": "newly identified"
                        }
                    },
                    {
                        "exact_snippets": "Appearance of newly identified, convincingly positive lesions",
                        "criterion": "lesions",
                        "requirement": {
                            "requirement_type": "positivity",
                            "expected_value": "convincingly positive"
                        }
                    },
                    {
                        "exact_snippets": "lesions consistent with metastatic prostate cancer",
                        "criterion": "lesion consistency with metastatic prostate cancer",
                        "requirement": {
                            "requirement_type": "consistency",
                            "expected_value": "metastatic prostate cancer"
                        }
                    },
                    {
                        "exact_snippets": "on PSMA PET",
                        "criterion": "lesion detection modality",
                        "requirement": {
                            "requirement_type": "detection modality",
                            "expected_value": "PSMA PET"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Any other condition which, in the opinion of the Investigator, would preclude participation in this trial.",
                "criterions": [
                    {
                        "exact_snippets": "Any other condition which, in the opinion of the Investigator, would preclude participation in this trial.",
                        "criterion": "other condition precluding participation (per Investigator judgment)",
                        "requirement": {
                            "requirement_type": "Investigator judgment",
                            "expected_value": "condition would preclude participation"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Any other condition which, in the opinion of the Investigator, would preclude participation in this trial.",
                        "criterion": "other condition precluding participation (per Investigator judgment)",
                        "requirement": {
                            "requirement_type": "Investigator judgment",
                            "expected_value": "condition would preclude participation"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Participants ≥ 18 years of age.",
                "criterions": [
                    {
                        "exact_snippets": "Participants ≥ 18 years of age",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Participants ≥ 18 years of age",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* History of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke, significant brain trauma). Also, history of loss of consciousness or transient ischemic attack within 12 months of randomization.",
                "criterions": [
                    {
                        "exact_snippets": "History of seizure",
                        "criterion": "seizure",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "any condition that may predispose to seizure (e.g., prior cortical stroke, significant brain trauma)",
                        "criterion": "condition predisposing to seizure",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "prior cortical stroke",
                        "criterion": "cortical stroke",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "significant brain trauma",
                        "criterion": "significant brain trauma",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of loss of consciousness",
                        "criterion": "loss of consciousness",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "transient ischemic attack within 12 months of randomization",
                        "criterion": "transient ischemic attack",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "History of seizure",
                                "criterion": "seizure",
                                "requirement": {
                                    "requirement_type": "history",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "any condition that may predispose to seizure (e.g., prior cortical stroke, significant brain trauma)",
                                "criterion": "condition predisposing to seizure",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "prior cortical stroke",
                                "criterion": "cortical stroke",
                                "requirement": {
                                    "requirement_type": "history",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "significant brain trauma",
                                "criterion": "significant brain trauma",
                                "requirement": {
                                    "requirement_type": "history",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "history of loss of consciousness",
                        "criterion": "loss of consciousness",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "transient ischemic attack within 12 months of randomization",
                        "criterion": "transient ischemic attack",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Known allergy to any of the compounds under investigation.",
                "criterions": [
                    {
                        "exact_snippets": "Known allergy to any of the compounds under investigation",
                        "criterion": "allergy to compounds under investigation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Known allergy to any of the compounds under investigation",
                        "criterion": "allergy to compounds under investigation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Serum glutamic pyruvic transaminase/ alanine transaminase (ALT) ≤ 2.5 x ULN",
                "criterions": [
                    {
                        "exact_snippets": "Serum glutamic pyruvic transaminase/ alanine transaminase (ALT) ≤ 2.5 x ULN",
                        "criterion": "alanine transaminase (ALT)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Serum glutamic pyruvic transaminase/ alanine transaminase (ALT) ≤ 2.5 x ULN",
                        "criterion": "alanine transaminase (ALT)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Soft tissue disease progression as defined by RECIST 1.1.",
                "criterions": [
                    {
                        "exact_snippets": "Soft tissue disease progression as defined by RECIST 1.1.",
                        "criterion": "soft tissue disease progression",
                        "requirement": {
                            "requirement_type": "progression_status",
                            "expected_value": "progression as defined by RECIST 1.1"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Soft tissue disease progression as defined by RECIST 1.1.",
                        "criterion": "soft tissue disease progression",
                        "requirement": {
                            "requirement_type": "progression_status",
                            "expected_value": "progression as defined by RECIST 1.1"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Participants treated with strong cytochrome P450 2C8 (CYP2C8) inhibitors (e.g., clopidogrel, gemfibrozil) within 7 days from randomization are not eligible.",
                "criterions": [
                    {
                        "exact_snippets": "Participants treated with strong cytochrome P450 2C8 (CYP2C8) inhibitors (e.g., clopidogrel, gemfibrozil) within 7 days from randomization",
                        "criterion": "treatment with strong CYP2C8 inhibitors",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days from randomization"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Participants treated with strong cytochrome P450 2C8 (CYP2C8) inhibitors (e.g., clopidogrel, gemfibrozil) within 7 days from randomization",
                        "criterion": "treatment with strong CYP2C8 inhibitors",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "and_criteria": [
                        {
                            "exact_snippets": "Participants treated with strong cytochrome P450 2C8 (CYP2C8) inhibitors (e.g., clopidogrel, gemfibrozil) within 7 days from randomization",
                            "criterion": "treatment with strong CYP2C8 inhibitors",
                            "requirement": {
                                "requirement_type": "recency",
                                "expected_value": {
                                    "operator": "<=",
                                    "value": 7,
                                    "unit": "days from randomization"
                                }
                            }
                        },
                        {
                            "exact_snippets": "Participants treated with strong cytochrome P450 2C8 (CYP2C8) inhibitors (e.g., clopidogrel, gemfibrozil) within 7 days from randomization",
                            "criterion": "treatment with strong CYP2C8 inhibitors",
                            "requirement": {
                                "requirement_type": "eligibility",
                                "expected_value": false
                            }
                        }
                    ]
                }
            }
        },
        {
            "identified_line": {
                "line": "* Unequivocal prostate-specific membrane antigen (PSMA) positron emission tomography (PET) only defined metastatic disease with negative conventional imaging. PSMA PET imaging is not required to be performed, but may be used to document metastases when relevant.",
                "criterions": [
                    {
                        "exact_snippets": "Unequivocal prostate-specific membrane antigen (PSMA) positron emission tomography (PET) only defined metastatic disease",
                        "criterion": "metastatic disease",
                        "requirement": {
                            "requirement_type": "detection_method",
                            "expected_value": "PSMA PET only"
                        }
                    },
                    {
                        "exact_snippets": "Unequivocal prostate-specific membrane antigen (PSMA) positron emission tomography (PET) only defined metastatic disease",
                        "criterion": "metastatic disease",
                        "requirement": {
                            "requirement_type": "unequivocal",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "negative conventional imaging",
                        "criterion": "conventional imaging for metastatic disease",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Unequivocal prostate-specific membrane antigen (PSMA) positron emission tomography (PET) only defined metastatic disease",
                        "criterion": "metastatic disease",
                        "requirement": {
                            "requirement_type": "detection_method",
                            "expected_value": "PSMA PET only"
                        }
                    },
                    {
                        "exact_snippets": "Unequivocal prostate-specific membrane antigen (PSMA) positron emission tomography (PET) only defined metastatic disease",
                        "criterion": "metastatic disease",
                        "requirement": {
                            "requirement_type": "unequivocal",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "negative conventional imaging",
                        "criterion": "conventional imaging for metastatic disease",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Are willing to be randomized into either study arm and adhere to the study protocol.",
                "criterions": [
                    {
                        "exact_snippets": "willing to be randomized into either study arm",
                        "criterion": "willingness to be randomized",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "adhere to the study protocol",
                        "criterion": "ability to adhere to study protocol",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "willing to be randomized into either study arm",
                        "criterion": "willingness to be randomized",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "adhere to the study protocol",
                        "criterion": "ability to adhere to study protocol",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Are willing to remain on study treatment and to continue undergoing study imaging despite PSA progression unless clinically deteriorating.",
                "criterions": [
                    {
                        "exact_snippets": "willing to remain on study treatment",
                        "criterion": "willingness to remain on study treatment",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willing ... to continue undergoing study imaging despite PSA progression unless clinically deteriorating",
                        "criterion": "willingness to continue undergoing study imaging despite PSA progression unless clinically deteriorating",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "willing to remain on study treatment",
                        "criterion": "willingness to remain on study treatment",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willing ... to continue undergoing study imaging despite PSA progression unless clinically deteriorating",
                        "criterion": "willingness to continue undergoing study imaging despite PSA progression unless clinically deteriorating",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Participants who received chemotherapy for castration-sensitive prostate cancer are still eligible provided chemotherapy was completed >6 months prior to start of study treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Participants who received chemotherapy for castration-sensitive prostate cancer are still eligible provided chemotherapy was completed >6 months prior to start of study treatment.",
                        "criterion": "prior chemotherapy for castration-sensitive prostate cancer",
                        "requirement": {
                            "requirement_type": "completion time before study treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Participants who received chemotherapy for castration-sensitive prostate cancer are still eligible provided chemotherapy was completed >6 months prior to start of study treatment.",
                        "criterion": "prior chemotherapy for castration-sensitive prostate cancer",
                        "requirement": {
                            "requirement_type": "completion time before study treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Bilirubin ≤ 1.3 x ULN (unless documented Gilbert's disease)",
                "criterions": [
                    {
                        "exact_snippets": "Bilirubin ≤ 1.3 x ULN",
                        "criterion": "bilirubin level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.3,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "unless documented Gilbert's disease",
                        "criterion": "Gilbert's disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "not_criteria": {
                        "not_criteria": {
                            "exact_snippets": "unless documented Gilbert's disease",
                            "criterion": "Gilbert's disease",
                            "requirement": {
                                "requirement_type": "presence",
                                "expected_value": true
                            }
                        }
                    }
                },
                "then_criteria": {
                    "exact_snippets": "Bilirubin ≤ 1.3 x ULN",
                    "criterion": "bilirubin level",
                    "requirement": {
                        "requirement_type": "quantity",
                        "expected_value": {
                            "operator": "<=",
                            "value": 1.3,
                            "unit": "x ULN"
                        }
                    }
                },
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "* Prior treatment with a PARP inhibitor.",
                "criterions": [
                    {
                        "exact_snippets": "Prior treatment with a PARP inhibitor.",
                        "criterion": "prior treatment with a PARP inhibitor",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Prior treatment with a PARP inhibitor.",
                        "criterion": "prior treatment with a PARP inhibitor",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Metastatic castration-resistant prostate cancer (mCRPC) as demonstrated by one of the following:",
                "criterions": [
                    {
                        "exact_snippets": "Metastatic castration-resistant prostate cancer (mCRPC)",
                        "criterion": "prostate cancer",
                        "requirement": {
                            "requirement_type": "metastatic",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Metastatic castration-resistant prostate cancer (mCRPC)",
                        "criterion": "prostate cancer",
                        "requirement": {
                            "requirement_type": "castration-resistant",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Metastatic castration-resistant prostate cancer (mCRPC)",
                        "criterion": "prostate cancer",
                        "requirement": {
                            "requirement_type": "metastatic",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Metastatic castration-resistant prostate cancer (mCRPC)",
                        "criterion": "prostate cancer",
                        "requirement": {
                            "requirement_type": "castration-resistant",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Eastern Cooperative Oncology Group (ECOG) status of ≤1 (Appendix A: Performance Status Criteria).",
                "criterions": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) status of ≤1",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) status of ≤1",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PSA progression defined as 2 rising PSA levels, above an initial reference value, taken with a minimum of a 1-week interval. If PSA rise is the only indication of progression at start of study treatment, a minimum PSA of 1.0 ng/mL is required and all measured PSA values have to be considered to make a determination of progression.",
                "criterions": [
                    {
                        "exact_snippets": "PSA progression defined as 2 rising PSA levels, above an initial reference value, taken with a minimum of a 1-week interval",
                        "criterion": "PSA progression",
                        "requirement": {
                            "requirement_type": "number of rising PSA levels",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    },
                    {
                        "exact_snippets": "PSA progression defined as 2 rising PSA levels, above an initial reference value, taken with a minimum of a 1-week interval",
                        "criterion": "PSA progression",
                        "requirement": {
                            "requirement_type": "comparison to reference value",
                            "expected_value": "above initial reference value"
                        }
                    },
                    {
                        "exact_snippets": "PSA progression defined as 2 rising PSA levels, above an initial reference value, taken with a minimum of a 1-week interval",
                        "criterion": "PSA progression",
                        "requirement": {
                            "requirement_type": "interval between measurements",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    },
                    {
                        "exact_snippets": "If PSA rise is the only indication of progression at start of study treatment, a minimum PSA of 1.0 ng/mL is required",
                        "criterion": "PSA level (if PSA rise is only indication of progression)",
                        "requirement": {
                            "requirement_type": "minimum PSA",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.0,
                                "unit": "ng/mL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "all measured PSA values have to be considered to make a determination of progression",
                        "criterion": "PSA measurement consideration",
                        "requirement": {
                            "requirement_type": "inclusion of all measured PSA values",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "PSA progression defined as 2 rising PSA levels, above an initial reference value, taken with a minimum of a 1-week interval",
                                "criterion": "PSA progression",
                                "requirement": {
                                    "requirement_type": "number of rising PSA levels",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "PSA progression defined as 2 rising PSA levels, above an initial reference value, taken with a minimum of a 1-week interval",
                                "criterion": "PSA progression",
                                "requirement": {
                                    "requirement_type": "comparison to reference value",
                                    "expected_value": "above initial reference value"
                                }
                            },
                            {
                                "exact_snippets": "PSA progression defined as 2 rising PSA levels, above an initial reference value, taken with a minimum of a 1-week interval",
                                "criterion": "PSA progression",
                                "requirement": {
                                    "requirement_type": "interval between measurements",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "week"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "condition": {
                            "exact_snippets": "If PSA rise is the only indication of progression at start of study treatment, a minimum PSA of 1.0 ng/mL is required",
                            "criterion": "PSA level (if PSA rise is only indication of progression)",
                            "requirement": {
                                "requirement_type": "minimum PSA",
                                "expected_value": {
                                    "operator": ">=",
                                    "value": 1.0,
                                    "unit": "ng/mL"
                                }
                            }
                        },
                        "then_criteria": null,
                        "else_criteria": null
                    },
                    {
                        "exact_snippets": "all measured PSA values have to be considered to make a determination of progression",
                        "criterion": "PSA measurement consideration",
                        "requirement": {
                            "requirement_type": "inclusion of all measured PSA values",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Serum glutamic oxaloacetic transaminase/aspartate transaminase (AST) ≤ 2.5 x ULN",
                "criterions": [
                    {
                        "exact_snippets": "Serum glutamic oxaloacetic transaminase/aspartate transaminase (AST) ≤ 2.5 x ULN",
                        "criterion": "aspartate transaminase (AST) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Serum glutamic oxaloacetic transaminase/aspartate transaminase (AST) ≤ 2.5 x ULN",
                        "criterion": "aspartate transaminase (AST) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Current use of strong cytochrome P450 2C8 (CYP2C8) inhibitors (e.g., clopidogrel, gemfibrozil) and inducers (e.g., rifampin), strong CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine and St. John's Wort), moderate CYP3A4 inducers (e.g., bosentan, efavirenz, etravirine, modafinil and nafcillin), or substrates of CYP3A4 (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus and tacrolimus), CYP2C9 (e.g., phenytoin, warfarin), or CYP2C19 (e.g., S-mephenytoin) with a narrow therapeutic index unless considered medically necessary to treat a life-threatening condition.",
                "criterions": [
                    {
                        "exact_snippets": "Current use of strong cytochrome P450 2C8 (CYP2C8) inhibitors (e.g., clopidogrel, gemfibrozil)",
                        "criterion": "use of strong CYP2C8 inhibitors",
                        "requirement": {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current use of strong cytochrome P450 2C8 (CYP2C8) ... inducers (e.g., rifampin)",
                        "criterion": "use of strong CYP2C8 inducers",
                        "requirement": {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "strong CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine and St. John's Wort)",
                        "criterion": "use of strong CYP3A4 inducers",
                        "requirement": {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "moderate CYP3A4 inducers (e.g., bosentan, efavirenz, etravirine, modafinil and nafcillin)",
                        "criterion": "use of moderate CYP3A4 inducers",
                        "requirement": {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "substrates of CYP3A4 (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus and tacrolimus)",
                        "criterion": "use of CYP3A4 substrates with a narrow therapeutic index",
                        "requirement": {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "substrates of CYP3A4 (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus and tacrolimus)",
                        "criterion": "use of CYP3A4 substrates with a narrow therapeutic index",
                        "requirement": {
                            "requirement_type": "narrow therapeutic index",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "CYP2C9 (e.g., phenytoin, warfarin)",
                        "criterion": "use of CYP2C9 substrates with a narrow therapeutic index",
                        "requirement": {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "CYP2C9 (e.g., phenytoin, warfarin)",
                        "criterion": "use of CYP2C9 substrates with a narrow therapeutic index",
                        "requirement": {
                            "requirement_type": "narrow therapeutic index",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "CYP2C19 (e.g., S-mephenytoin) with a narrow therapeutic index",
                        "criterion": "use of CYP2C19 substrates with a narrow therapeutic index",
                        "requirement": {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "CYP2C19 (e.g., S-mephenytoin) with a narrow therapeutic index",
                        "criterion": "use of CYP2C19 substrates with a narrow therapeutic index",
                        "requirement": {
                            "requirement_type": "narrow therapeutic index",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "or_criteria": [
                            {
                                "or_criteria": [
                                    {
                                        "or_criteria": [
                                            {
                                                "or_criteria": [
                                                    {
                                                        "or_criteria": [
                                                            {
                                                                "or_criteria": [
                                                                    {
                                                                        "or_criteria": [
                                                                            {
                                                                                "and_criteria": [
                                                                                    {
                                                                                        "exact_snippets": "Current use of strong cytochrome P450 2C8 (CYP2C8) inhibitors (e.g., clopidogrel, gemfibrozil)",
                                                                                        "criterion": "use of strong CYP2C8 inhibitors",
                                                                                        "requirement": {
                                                                                            "requirement_type": "current use",
                                                                                            "expected_value": true
                                                                                        }
                                                                                    },
                                                                                    {
                                                                                        "exact_snippets": "Current use of strong cytochrome P450 2C8 (CYP2C8) ... inducers (e.g., rifampin)",
                                                                                        "criterion": "use of strong CYP2C8 inducers",
                                                                                        "requirement": {
                                                                                            "requirement_type": "current use",
                                                                                            "expected_value": true
                                                                                        }
                                                                                    }
                                                                                ]
                                                                            },
                                                                            {
                                                                                "exact_snippets": "strong CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine and St. John's Wort)",
                                                                                "criterion": "use of strong CYP3A4 inducers",
                                                                                "requirement": {
                                                                                    "requirement_type": "current use",
                                                                                    "expected_value": true
                                                                                }
                                                                            }
                                                                        ]
                                                                    },
                                                                    {
                                                                        "exact_snippets": "moderate CYP3A4 inducers (e.g., bosentan, efavirenz, etravirine, modafinil and nafcillin)",
                                                                        "criterion": "use of moderate CYP3A4 inducers",
                                                                        "requirement": {
                                                                            "requirement_type": "current use",
                                                                            "expected_value": true
                                                                        }
                                                                    }
                                                                ]
                                                            },
                                                            {
                                                                "and_criteria": [
                                                                    {
                                                                        "exact_snippets": "substrates of CYP3A4 (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus and tacrolimus)",
                                                                        "criterion": "use of CYP3A4 substrates with a narrow therapeutic index",
                                                                        "requirement": {
                                                                            "requirement_type": "current use",
                                                                            "expected_value": true
                                                                        }
                                                                    },
                                                                    {
                                                                        "exact_snippets": "substrates of CYP3A4 (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus and tacrolimus)",
                                                                        "criterion": "use of CYP3A4 substrates with a narrow therapeutic index",
                                                                        "requirement": {
                                                                            "requirement_type": "narrow therapeutic index",
                                                                            "expected_value": true
                                                                        }
                                                                    }
                                                                ]
                                                            }
                                                        ]
                                                    },
                                                    {
                                                        "and_criteria": [
                                                            {
                                                                "exact_snippets": "CYP2C9 (e.g., phenytoin, warfarin)",
                                                                "criterion": "use of CYP2C9 substrates with a narrow therapeutic index",
                                                                "requirement": {
                                                                    "requirement_type": "current use",
                                                                    "expected_value": true
                                                                }
                                                            },
                                                            {
                                                                "exact_snippets": "CYP2C9 (e.g., phenytoin, warfarin)",
                                                                "criterion": "use of CYP2C9 substrates with a narrow therapeutic index",
                                                                "requirement": {
                                                                    "requirement_type": "narrow therapeutic index",
                                                                    "expected_value": true
                                                                }
                                                            }
                                                        ]
                                                    }
                                                ]
                                            },
                                            {
                                                "and_criteria": [
                                                    {
                                                        "exact_snippets": "CYP2C19 (e.g., S-mephenytoin) with a narrow therapeutic index",
                                                        "criterion": "use of CYP2C19 substrates with a narrow therapeutic index",
                                                        "requirement": {
                                                            "requirement_type": "current use",
                                                            "expected_value": true
                                                        }
                                                    },
                                                    {
                                                        "exact_snippets": "CYP2C19 (e.g., S-mephenytoin) with a narrow therapeutic index",
                                                        "criterion": "use of CYP2C19 substrates with a narrow therapeutic index",
                                                        "requirement": {
                                                            "requirement_type": "narrow therapeutic index",
                                                            "expected_value": true
                                                        }
                                                    }
                                                ]
                                            }
                                        ]
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Concurrent treatment with crizotinib.",
                "criterions": [
                    {
                        "exact_snippets": "Concurrent treatment with crizotinib",
                        "criterion": "crizotinib treatment",
                        "requirement": {
                            "requirement_type": "concurrent use",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Concurrent treatment with crizotinib",
                        "criterion": "crizotinib treatment",
                        "requirement": {
                            "requirement_type": "concurrent use",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Prior platinum-based chemotherapy for the treatment of prostate cancer.",
                "criterions": [
                    {
                        "exact_snippets": "Prior platinum-based chemotherapy for the treatment of prostate cancer.",
                        "criterion": "platinum-based chemotherapy for prostate cancer",
                        "requirement": {
                            "requirement_type": "history of prior treatment",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Prior platinum-based chemotherapy for the treatment of prostate cancer.",
                        "criterion": "platinum-based chemotherapy for prostate cancer",
                        "requirement": {
                            "requirement_type": "history of prior treatment",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Inclusion Criteria",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        },
        {
            "identified_line": {
                "line": "* Medical conditions such as uncontrolled hypertension as indicated by a resting systolic blood pressure > 160 mm Hg or diastolic blood pressure > 90 mm Hg at screening, uncontrolled diabetes mellitus, and cardiac disease that would preclude participation, as determined by the investigator.",
                "criterions": [
                    {
                        "exact_snippets": "uncontrolled hypertension as indicated by a resting systolic blood pressure > 160 mm Hg or diastolic blood pressure > 90 mm Hg at screening",
                        "criterion": "blood pressure",
                        "requirement": {
                            "requirement_type": "systolic blood pressure",
                            "expected_value": {
                                "operator": ">",
                                "value": 160,
                                "unit": "mm Hg"
                            }
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled hypertension as indicated by a resting systolic blood pressure > 160 mm Hg or diastolic blood pressure > 90 mm Hg at screening",
                        "criterion": "blood pressure",
                        "requirement": {
                            "requirement_type": "diastolic blood pressure",
                            "expected_value": {
                                "operator": ">",
                                "value": 90,
                                "unit": "mm Hg"
                            }
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled diabetes mellitus",
                        "criterion": "diabetes mellitus",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "cardiac disease that would preclude participation, as determined by the investigator",
                        "criterion": "cardiac disease",
                        "requirement": {
                            "requirement_type": "severity/impact",
                            "expected_value": "would preclude participation as determined by the investigator"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "uncontrolled hypertension as indicated by a resting systolic blood pressure > 160 mm Hg or diastolic blood pressure > 90 mm Hg at screening",
                                "criterion": "blood pressure",
                                "requirement": {
                                    "requirement_type": "systolic blood pressure",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 160,
                                        "unit": "mm Hg"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "uncontrolled hypertension as indicated by a resting systolic blood pressure > 160 mm Hg or diastolic blood pressure > 90 mm Hg at screening",
                                "criterion": "blood pressure",
                                "requirement": {
                                    "requirement_type": "diastolic blood pressure",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 90,
                                        "unit": "mm Hg"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "uncontrolled diabetes mellitus",
                        "criterion": "diabetes mellitus",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "cardiac disease that would preclude participation, as determined by the investigator",
                        "criterion": "cardiac disease",
                        "requirement": {
                            "requirement_type": "severity/impact",
                            "expected_value": "would preclude participation as determined by the investigator"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Use of herbal products or alternative therapies that may decrease PSA levels or that may have hormonal anti-prostate cancer activity (e.g., saw palmetto, PC-SPES, PC-HOPE, St. John's wort, selenium supplements, grape seed extract, etc.) within 28 days of study treatment initiation or plans to initiate treatment with these products/alternative therapies during the entire duration of the study.",
                "criterions": [
                    {
                        "exact_snippets": "Use of herbal products or alternative therapies that may decrease PSA levels or that may have hormonal anti-prostate cancer activity (e.g., saw palmetto, PC-SPES, PC-HOPE, St. John's wort, selenium supplements, grape seed extract, etc.) within 28 days of study treatment initiation",
                        "criterion": "use of herbal products or alternative therapies that may decrease PSA levels or have hormonal anti-prostate cancer activity",
                        "requirement": {
                            "requirement_type": "use within 28 days prior to study treatment initiation",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "plans to initiate treatment with these products/alternative therapies during the entire duration of the study",
                        "criterion": "planned use of herbal products or alternative therapies that may decrease PSA levels or have hormonal anti-prostate cancer activity",
                        "requirement": {
                            "requirement_type": "planned use during study",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Use of herbal products or alternative therapies that may decrease PSA levels or that may have hormonal anti-prostate cancer activity (e.g., saw palmetto, PC-SPES, PC-HOPE, St. John's wort, selenium supplements, grape seed extract, etc.) within 28 days of study treatment initiation",
                        "criterion": "use of herbal products or alternative therapies that may decrease PSA levels or have hormonal anti-prostate cancer activity",
                        "requirement": {
                            "requirement_type": "use within 28 days prior to study treatment initiation",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "plans to initiate treatment with these products/alternative therapies during the entire duration of the study",
                        "criterion": "planned use of herbal products or alternative therapies that may decrease PSA levels or have hormonal anti-prostate cancer activity",
                        "requirement": {
                            "requirement_type": "planned use during study",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Ability to swallow study capsules and/or tablets whole.",
                "criterions": [
                    {
                        "exact_snippets": "Ability to swallow study capsules and/or tablets whole",
                        "criterion": "ability to swallow study capsules and/or tablets whole",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Ability to swallow study capsules and/or tablets whole",
                        "criterion": "ability to swallow study capsules and/or tablets whole",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Exclusion Criteria",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        },
        {
            "identified_line": {
                "line": "* Bone disease progression defined by PCWG3 with 2 or more new metastatic bone lesions on a whole-body radionuclide bone scan.",
                "criterions": [
                    {
                        "exact_snippets": "Bone disease progression defined by PCWG3",
                        "criterion": "bone disease progression",
                        "requirement": {
                            "requirement_type": "definition",
                            "expected_value": "PCWG3"
                        }
                    },
                    {
                        "exact_snippets": "2 or more new metastatic bone lesions",
                        "criterion": "number of new metastatic bone lesions",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "lesions"
                            }
                        }
                    },
                    {
                        "exact_snippets": "on a whole-body radionuclide bone scan",
                        "criterion": "detection method for bone lesions",
                        "requirement": {
                            "requirement_type": "method",
                            "expected_value": "whole-body radionuclide bone scan"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Bone disease progression defined by PCWG3",
                        "criterion": "bone disease progression",
                        "requirement": {
                            "requirement_type": "definition",
                            "expected_value": "PCWG3"
                        }
                    },
                    {
                        "exact_snippets": "2 or more new metastatic bone lesions",
                        "criterion": "number of new metastatic bone lesions",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "lesions"
                            }
                        }
                    },
                    {
                        "exact_snippets": "on a whole-body radionuclide bone scan",
                        "criterion": "detection method for bone lesions",
                        "requirement": {
                            "requirement_type": "method",
                            "expected_value": "whole-body radionuclide bone scan"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "• Willing and able to provide, or have a legally authorized representative provide, written informed consent and privacy authorization for the release of personal health information. A signed informed consent must be obtained before screening procedures are performed.",
                "criterions": [
                    {
                        "exact_snippets": "Willing and able to provide ... written informed consent",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Willing and able to provide ... written informed consent",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Willing and able to provide ... written informed consent",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willing and able to provide ... privacy authorization for the release of personal health information",
                        "criterion": "privacy authorization for release of personal health information",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willing and able to provide ... privacy authorization for the release of personal health information",
                        "criterion": "privacy authorization for release of personal health information",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "or have a legally authorized representative provide ... written informed consent and privacy authorization",
                        "criterion": "legally authorized representative consent/authorization",
                        "requirement": {
                            "requirement_type": "legally authorized representative",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "or have a legally authorized representative provide ... written informed consent and privacy authorization",
                        "criterion": "legally authorized representative consent/authorization",
                        "requirement": {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Willing and able to provide ... written informed consent",
                                "criterion": "informed consent",
                                "requirement": {
                                    "requirement_type": "willingness",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Willing and able to provide ... written informed consent",
                                "criterion": "informed consent",
                                "requirement": {
                                    "requirement_type": "ability",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Willing and able to provide ... written informed consent",
                                "criterion": "informed consent",
                                "requirement": {
                                    "requirement_type": "signed",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "willing and able to provide ... privacy authorization for the release of personal health information",
                                "criterion": "privacy authorization for release of personal health information",
                                "requirement": {
                                    "requirement_type": "willingness",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "willing and able to provide ... privacy authorization for the release of personal health information",
                                "criterion": "privacy authorization for release of personal health information",
                                "requirement": {
                                    "requirement_type": "ability",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "or have a legally authorized representative provide ... written informed consent and privacy authorization",
                                "criterion": "legally authorized representative consent/authorization",
                                "requirement": {
                                    "requirement_type": "legally authorized representative",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "or have a legally authorized representative provide ... written informed consent and privacy authorization",
                                "criterion": "legally authorized representative consent/authorization",
                                "requirement": {
                                    "requirement_type": "signed",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "* Grade >2 treatment-related toxicity from prior therapy except alopecia or peripheral neuropathy.",
                "criterions": [
                    {
                        "exact_snippets": "Grade >2 treatment-related toxicity from prior therapy except alopecia or peripheral neuropathy",
                        "criterion": "treatment-related toxicity from prior therapy",
                        "requirement": {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Grade >2 treatment-related toxicity from prior therapy except alopecia or peripheral neuropathy",
                        "criterion": "treatment-related toxicity from prior therapy",
                        "requirement": {
                            "requirement_type": "exclusion",
                            "expected_value": [
                                "alopecia",
                                "peripheral neuropathy"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Participants receiving a blood transfusion within 14 days of randomization are not eligible.",
                "criterions": [
                    {
                        "exact_snippets": "Participants receiving a blood transfusion within 14 days of randomization are not eligible.",
                        "criterion": "blood transfusion",
                        "requirement": {
                            "requirement_type": "timing relative to randomization",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Participants receiving a blood transfusion within 14 days of randomization are not eligible.",
                        "criterion": "blood transfusion",
                        "requirement": {
                            "requirement_type": "receipt",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "not_criteria": {
                            "and_criteria": [
                                {
                                    "exact_snippets": "Participants receiving a blood transfusion within 14 days of randomization are not eligible.",
                                    "criterion": "blood transfusion",
                                    "requirement": {
                                        "requirement_type": "timing relative to randomization",
                                        "expected_value": {
                                            "operator": "<=",
                                            "value": 14,
                                            "unit": "days"
                                        }
                                    }
                                },
                                {
                                    "exact_snippets": "Participants receiving a blood transfusion within 14 days of randomization are not eligible.",
                                    "criterion": "blood transfusion",
                                    "requirement": {
                                        "requirement_type": "receipt",
                                        "expected_value": true
                                    }
                                }
                            ]
                        }
                    },
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "Participants receiving a blood transfusion within 14 days of randomization are not eligible.",
                                "criterion": "blood transfusion",
                                "requirement": {
                                    "requirement_type": "timing relative to randomization",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 14,
                                        "unit": "days"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Participants receiving a blood transfusion within 14 days of randomization are not eligible.",
                                "criterion": "blood transfusion",
                                "requirement": {
                                    "requirement_type": "receipt",
                                    "expected_value": false
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Received prior abiraterone acetate with prednisone for mHSPC or locally advanced disease and on which progressed via a minimum of 2 rising PSA levels with a minimum of a 1-week interval between each determination or radiographic progression by any form of imaging.",
                "criterions": [
                    {
                        "exact_snippets": "Received prior abiraterone acetate with prednisone for mHSPC or locally advanced disease",
                        "criterion": "prior abiraterone acetate with prednisone treatment",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Received prior abiraterone acetate with prednisone for mHSPC or locally advanced disease",
                        "criterion": "prior abiraterone acetate with prednisone treatment",
                        "requirement": {
                            "requirement_type": "indication",
                            "expected_value": [
                                "mHSPC",
                                "locally advanced disease"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "progressed via a minimum of 2 rising PSA levels with a minimum of a 1-week interval between each determination",
                        "criterion": "PSA progression",
                        "requirement": {
                            "requirement_type": "number of rising PSA levels",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "levels"
                            }
                        }
                    },
                    {
                        "exact_snippets": "progressed via a minimum of 2 rising PSA levels with a minimum of a 1-week interval between each determination",
                        "criterion": "PSA progression",
                        "requirement": {
                            "requirement_type": "interval between PSA determinations",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    },
                    {
                        "exact_snippets": "or radiographic progression by any form of imaging",
                        "criterion": "radiographic progression",
                        "requirement": {
                            "requirement_type": "progression by imaging",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Hemoglobin ≥ 9g/dl",
                "criterions": [
                    {
                        "exact_snippets": "Hemoglobin ≥ 9g/dl",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dl"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Hemoglobin \u001e 9g/dl",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dl"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Creatinine ≤ 1.5 x the institutional upper limit of normal (ULN)",
                "criterions": [
                    {
                        "exact_snippets": "Creatinine ≤ 1.5 x the institutional upper limit of normal (ULN)",
                        "criterion": "creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Creatinine \u00104 1.5 x the institutional upper limit of normal (ULN)",
                        "criterion": "creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Current or planned use of potent P-gp inhibitors within 7 days prior to randomization. The P-gp inhibitors include: amiodarone, carvedilol, clarithromycin, cobicistat, dronedarone, erythromycin, glecaprevir/pibrentasvir, indinavir, itraconazole, ketoconazole, lapatinib, lopinavir, propafenone, quinidine, ranolazine, ritonavir, saquinavir, sofosbuvir/velpatasvir/voxilaprevir, telaprevir, tipranavir, valspodar, and verapamil.",
                "criterions": [
                    {
                        "exact_snippets": "Current or planned use of potent P-gp inhibitors within 7 days prior to randomization. The P-gp inhibitors include: amiodarone, carvedilol, clarithromycin, cobicistat, dronedarone, erythromycin, glecaprevir/pibrentasvir, indinavir, itraconazole, ketoconazole, lapatinib, lopinavir, propafenone, quinidine, ranolazine, ritonavir, saquinavir, sofosbuvir/velpatasvir/voxilaprevir, telaprevir, tipranavir, valspodar, and verapamil.",
                        "criterion": "use of potent P-gp inhibitors",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current or planned use of potent P-gp inhibitors within 7 days prior to randomization. The P-gp inhibitors include: amiodarone, carvedilol, clarithromycin, cobicistat, dronedarone, erythromycin, glecaprevir/pibrentasvir, indinavir, itraconazole, ketoconazole, lapatinib, lopinavir, propafenone, quinidine, ranolazine, ritonavir, saquinavir, sofosbuvir/velpatasvir/voxilaprevir, telaprevir, tipranavir, valspodar, and verapamil.",
                        "criterion": "use of potent P-gp inhibitors",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to randomization"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Current or planned use of potent P-gp inhibitors within 7 days prior to randomization. The P-gp inhibitors include: amiodarone, carvedilol, clarithromycin, cobicistat, dronedarone, erythromycin, glecaprevir/pibrentasvir, indinavir, itraconazole, ketoconazole, lapatinib, lopinavir, propafenone, quinidine, ranolazine, ritonavir, saquinavir, sofosbuvir/velpatasvir/voxilaprevir, telaprevir, tipranavir, valspodar, and verapamil.",
                        "criterion": "use of potent P-gp inhibitors",
                        "requirement": {
                            "requirement_type": "drug_list",
                            "expected_value": [
                                "amiodarone",
                                "carvedilol",
                                "clarithromycin",
                                "cobicistat",
                                "dronedarone",
                                "erythromycin",
                                "glecaprevir/pibrentasvir",
                                "indinavir",
                                "itraconazole",
                                "ketoconazole",
                                "lapatinib",
                                "lopinavir",
                                "propafenone",
                                "quinidine",
                                "ranolazine",
                                "ritonavir",
                                "saquinavir",
                                "sofosbuvir/velpatasvir/voxilaprevir",
                                "telaprevir",
                                "tipranavir",
                                "valspodar",
                                "verapamil"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Use of hormonal agents with anti-tumor activity against prostate cancer including 5-alpha reductase inhibitors, androgens (e.g., testosterone), cytoproterone acetate, progestational agents, and estrogens/diethylstilbestrol within 28 days prior to the start of study treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Use of hormonal agents with anti-tumor activity against prostate cancer including 5-alpha reductase inhibitors, androgens (e.g., testosterone), cytoproterone acetate, progestational agents, and estrogens/diethylstilbestrol within 28 days prior to the start of study treatment.",
                        "criterion": "use of hormonal agents with anti-tumor activity against prostate cancer",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to the start of study treatment"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Use of hormonal agents with anti-tumor activity against prostate cancer including 5-alpha reductase inhibitors, androgens (e.g., testosterone), cytoproterone acetate, progestational agents, and estrogens/diethylstilbestrol within 28 days prior to the start of study treatment.",
                        "criterion": "use of hormonal agents with anti-tumor activity against prostate cancer",
                        "requirement": {
                            "requirement_type": "agent_types",
                            "expected_value": [
                                "5-alpha reductase inhibitors",
                                "androgens (e.g., testosterone)",
                                "cytoproterone acetate",
                                "progestational agents",
                                "estrogens/diethylstilbestrol"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Histological or cytological proof of adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features.",
                "criterions": [
                    {
                        "exact_snippets": "Histological or cytological proof of adenocarcinoma of the prostate",
                        "criterion": "adenocarcinoma of the prostate",
                        "requirement": {
                            "requirement_type": "diagnosis_method",
                            "expected_value": [
                                "histological proof",
                                "cytological proof"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "without neuroendocrine differentiation or small cell features",
                        "criterion": "neuroendocrine differentiation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "without neuroendocrine differentiation or small cell features",
                        "criterion": "small cell features",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Metastatic disease documented by conventional imaging: computed tomography (CT)/magnetic resonance imaging (MRI) chest/abdomen/pelvis and bone scan are required to be performed, but metastases do not need to be seen on both modalities. Measurable disease is not required.",
                "criterions": [
                    {
                        "exact_snippets": "Metastatic disease documented by conventional imaging",
                        "criterion": "metastatic disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Metastatic disease documented by conventional imaging",
                        "criterion": "metastatic disease",
                        "requirement": {
                            "requirement_type": "documentation_method",
                            "expected_value": [
                                "conventional imaging"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "computed tomography (CT)/magnetic resonance imaging (MRI) chest/abdomen/pelvis and bone scan are required to be performed",
                        "criterion": "imaging procedures",
                        "requirement": {
                            "requirement_type": "procedures_required",
                            "expected_value": [
                                "CT chest/abdomen/pelvis",
                                "MRI chest/abdomen/pelvis",
                                "bone scan"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "metastases do not need to be seen on both modalities",
                        "criterion": "metastases detection on imaging modalities",
                        "requirement": {
                            "requirement_type": "detection_on_both_modalities",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Measurable disease is not required",
                        "criterion": "measurable disease",
                        "requirement": {
                            "requirement_type": "requirement",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Absolute neutrophil count ≥ 1,500/µl",
                "criterions": [
                    {
                        "exact_snippets": "Absolute neutrophil count ≥ 1,500/µl",
                        "criterion": "absolute neutrophil count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "/µl"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Absolute neutrophil count \u001e 1,500/\u001bl",
                        "criterion": "absolute neutrophil count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "/\u001bl"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Platelet count ≥ 100,000/µl",
                "criterions": [
                    {
                        "exact_snippets": "Platelet count ≥ 100,000/µl",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "/µl"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Platelet count \u001e 100,000/\u00181",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "/\u00181"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Potassium ≥ 3.5 mmol/L (within institutional normal range)",
                "criterions": [
                    {
                        "exact_snippets": "Potassium ≥ 3.5 mmol/L (within institutional normal range)",
                        "criterion": "potassium level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3.5,
                                "unit": "mmol/L"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Potassium ≥ 3.5 mmol/L (within institutional normal range)",
                        "criterion": "potassium level",
                        "requirement": {
                            "requirement_type": "within institutional normal range",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Potassium \u001e 3.5 mmol/L (within institutional normal range)",
                        "criterion": "potassium level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3.5,
                                "unit": "mmol/L"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Potassium \u001e 3.5 mmol/L (within institutional normal range)",
                        "criterion": "potassium level",
                        "requirement": {
                            "requirement_type": "within institutional normal range",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Participants must agree to use a medically acceptable method of birth control (e.g., spermicide in conjunction with a barrier such as a condom) or sexual abstinence for the duration of the study, including 4 months after the last dose of study drug. Sperm donation is prohibited during the study and for 4 months after the last dose of study drug. Female partners must use hormonal or barrier contraception unless postmenopausal or abstinent.",
                "criterions": [
                    {
                        "exact_snippets": "Participants must agree to use a medically acceptable method of birth control (e.g., spermicide in conjunction with a barrier such as a condom) or sexual abstinence for the duration of the study, including 4 months after the last dose of study drug.",
                        "criterion": "birth control method or sexual abstinence",
                        "requirement": {
                            "requirement_type": "agreement",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Participants must agree to use a medically acceptable method of birth control (e.g., spermicide in conjunction with a barrier such as a condom) or sexual abstinence for the duration of the study, including 4 months after the last dose of study drug.",
                        "criterion": "birth control method or sexual abstinence",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": "for the duration of the study, including 4 months after the last dose of study drug"
                        }
                    },
                    {
                        "exact_snippets": "Sperm donation is prohibited during the study and for 4 months after the last dose of study drug.",
                        "criterion": "sperm donation",
                        "requirement": {
                            "requirement_type": "prohibition",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Sperm donation is prohibited during the study and for 4 months after the last dose of study drug.",
                        "criterion": "sperm donation",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": "during the study and for 4 months after the last dose of study drug"
                        }
                    },
                    {
                        "exact_snippets": "Female partners must use hormonal or barrier contraception unless postmenopausal or abstinent.",
                        "criterion": "contraception method for female partners",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": [
                                "hormonal contraception",
                                "barrier contraception"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Female partners must use hormonal or barrier contraception unless postmenopausal or abstinent.",
                        "criterion": "contraception method for female partners",
                        "requirement": {
                            "requirement_type": "exceptions",
                            "expected_value": [
                                "postmenopausal",
                                "abstinent"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Surgically or medically castrated, with testosterone levels of <50 ng/dL. If the participant is medically castrated, continuous dosing with a gonadotropin-releasing hormone agonist or antagonist must be demonstrated by testosterone level of <50 ng/dL and planned to continue throughout study participation.",
                "criterions": [
                    {
                        "exact_snippets": "Surgically or medically castrated",
                        "criterion": "castration status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": [
                                "surgically castrated",
                                "medically castrated"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "testosterone levels of <50 ng/dL",
                        "criterion": "testosterone level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "ng/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "If the participant is medically castrated, continuous dosing with a gonadotropin-releasing hormone agonist or antagonist must be demonstrated",
                        "criterion": "gonadotropin-releasing hormone agonist or antagonist dosing",
                        "requirement": {
                            "requirement_type": "continuous dosing",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "planned to continue throughout study participation",
                        "criterion": "gonadotropin-releasing hormone agonist or antagonist dosing",
                        "requirement": {
                            "requirement_type": "planned continuation",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Any other active malignancy at time of first dose of study treatment or diagnosis of another malignancy within 3 years prior to first dose of study treatment that requires active treatment, except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer or superficial bladder cancer.",
                "criterions": [
                    {
                        "exact_snippets": "Any other active malignancy at time of first dose of study treatment",
                        "criterion": "active malignancy (other than index cancer)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "diagnosis of another malignancy within 3 years prior to first dose of study treatment that requires active treatment",
                        "criterion": "diagnosis of another malignancy within 3 years prior to first dose",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "diagnosis of another malignancy within 3 years prior to first dose of study treatment that requires active treatment",
                        "criterion": "diagnosis of another malignancy within 3 years prior to first dose",
                        "requirement": {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "diagnosis of another malignancy within 3 years prior to first dose of study treatment that requires active treatment",
                        "criterion": "diagnosis of another malignancy within 3 years prior to first dose",
                        "requirement": {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer or superficial bladder cancer",
                        "criterion": "history of locally curable cancers that have been apparently cured (e.g., basal or squamous cell skin cancer, superficial bladder cancer)",
                        "requirement": {
                            "requirement_type": "exclusion from above malignancy criteria",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "active malignancy at time of first dose of study treatment",
                                "criterion": "active malignancy (other than index cancer)",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer or superficial bladder cancer",
                                "criterion": "history of locally curable cancers that have been apparently cured (e.g., basal or squamous cell skin cancer, superficial bladder cancer)",
                                "requirement": {
                                    "requirement_type": "exclusion from above malignancy criteria",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "diagnosis of another malignancy within 3 years prior to first dose of study treatment that requires active treatment",
                                "criterion": "diagnosis of another malignancy within 3 years prior to first dose",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer or superficial bladder cancer",
                                "criterion": "history of locally curable cancers that have been apparently cured (e.g., basal or squamous cell skin cancer, superficial bladder cancer)",
                                "requirement": {
                                    "requirement_type": "exclusion from above malignancy criteria",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Untreated known or suspected brain metastases or spinal cord compression or clinically significant malignant epidural disease.",
                "criterions": [
                    {
                        "exact_snippets": "Untreated known or suspected brain metastases",
                        "criterion": "brain metastases",
                        "requirement": {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    },
                    {
                        "exact_snippets": "Untreated known or suspected brain metastases",
                        "criterion": "brain metastases",
                        "requirement": {
                            "requirement_type": "diagnosis status",
                            "expected_value": [
                                "known",
                                "suspected"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "spinal cord compression",
                        "criterion": "spinal cord compression",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "clinically significant malignant epidural disease",
                        "criterion": "malignant epidural disease",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Progressive disease at start of treatment and in the setting of medical or surgical castration as defined by 1 or more of the following 4 criteria:",
                "criterions": [
                    {
                        "exact_snippets": "Progressive disease at start of treatment",
                        "criterion": "progressive disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Progressive disease at start of treatment",
                        "criterion": "progressive disease",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "at start of treatment"
                        }
                    },
                    {
                        "exact_snippets": "in the setting of medical or surgical castration",
                        "criterion": "castration",
                        "requirement": {
                            "requirement_type": "method",
                            "expected_value": [
                                "medical",
                                "surgical"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "in the setting of medical or surgical castration",
                        "criterion": "castration",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "present"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Presence of a pathogenic homologous recombination repair mutation in at least one of the following genes on tumor tissue or circulating tumor DNA testing: BRCA1, BRCA2, ATM (limited to 15% of enrolled participants), CDK12, CHEK2, PALB2, MLH1, NBN, ATR, FANCA, MRE11A, RAD51C. Assessment of HRR mutation status by germline or somatic testing. All testing must be per Clinical Laboratory Improvement Amendments (CLIA)-certified assay and may have occurred at any time prior to or at screening (not required to be completed within the screening window).",
                "criterions": [
                    {
                        "exact_snippets": "Presence of a pathogenic homologous recombination repair mutation in at least one of the following genes ... BRCA1, BRCA2, ATM (limited to 15% of enrolled participants), CDK12, CHEK2, PALB2, MLH1, NBN, ATR, FANCA, MRE11A, RAD51C",
                        "criterion": "homologous recombination repair (HRR) gene mutation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Presence of a pathogenic homologous recombination repair mutation in at least one of the following genes ... BRCA1, BRCA2, ATM (limited to 15% of enrolled participants), CDK12, CHEK2, PALB2, MLH1, NBN, ATR, FANCA, MRE11A, RAD51C",
                        "criterion": "homologous recombination repair (HRR) gene mutation",
                        "requirement": {
                            "requirement_type": "pathogenicity",
                            "expected_value": "pathogenic"
                        }
                    },
                    {
                        "exact_snippets": "Presence of a pathogenic homologous recombination repair mutation in at least one of the following genes ... BRCA1, BRCA2, ATM (limited to 15% of enrolled participants), CDK12, CHEK2, PALB2, MLH1, NBN, ATR, FANCA, MRE11A, RAD51C",
                        "criterion": "homologous recombination repair (HRR) gene mutation",
                        "requirement": {
                            "requirement_type": "gene",
                            "expected_value": [
                                "BRCA1",
                                "BRCA2",
                                "ATM",
                                "CDK12",
                                "CHEK2",
                                "PALB2",
                                "MLH1",
                                "NBN",
                                "ATR",
                                "FANCA",
                                "MRE11A",
                                "RAD51C"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "on tumor tissue or circulating tumor DNA testing",
                        "criterion": "HRR mutation detection method",
                        "requirement": {
                            "requirement_type": "sample type",
                            "expected_value": [
                                "tumor tissue",
                                "circulating tumor DNA"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "ATM (limited to 15% of enrolled participants)",
                        "criterion": "ATM mutation participant proportion",
                        "requirement": {
                            "requirement_type": "enrollment limit",
                            "expected_value": {
                                "operator": "<=",
                                "value": 15,
                                "unit": "% of enrolled participants"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Assessment of HRR mutation status by germline or somatic testing",
                        "criterion": "HRR mutation assessment type",
                        "requirement": {
                            "requirement_type": "testing type",
                            "expected_value": [
                                "germline",
                                "somatic"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "All testing must be per Clinical Laboratory Improvement Amendments (CLIA)-certified assay",
                        "criterion": "HRR mutation testing certification",
                        "requirement": {
                            "requirement_type": "certification",
                            "expected_value": "CLIA-certified"
                        }
                    },
                    {
                        "exact_snippets": "may have occurred at any time prior to or at screening (not required to be completed within the screening window)",
                        "criterion": "HRR mutation testing timing",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "any time prior to or at screening"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Prior treatment for metastatic or non-metastatic CRPC with an ARPI other than abiraterone acetate with prednisone for ≥ 12 weeks. Prior treatment with abiraterone acetate with prednisone in the mHSPC or locally advanced setting is not exclusionary.",
                "criterions": [
                    {
                        "exact_snippets": "Prior treatment for metastatic or non-metastatic CRPC with an ARPI other than abiraterone acetate with prednisone for ≥ 12 weeks.",
                        "criterion": "prior ARPI treatment (excluding abiraterone acetate with prednisone) for CRPC",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment for metastatic or non-metastatic CRPC with an ARPI other than abiraterone acetate with prednisone for ≥ 12 weeks.",
                        "criterion": "prior ARPI treatment (excluding abiraterone acetate with prednisone) for CRPC",
                        "requirement": {
                            "requirement_type": "treatment duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment for metastatic or non-metastatic CRPC with an ARPI other than abiraterone acetate with prednisone for ≥ 12 weeks.",
                        "criterion": "prior ARPI treatment (excluding abiraterone acetate with prednisone) for CRPC",
                        "requirement": {
                            "requirement_type": "treatment agent",
                            "expected_value": "ARPI other than abiraterone acetate with prednisone"
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment for metastatic or non-metastatic CRPC with an ARPI other than abiraterone acetate with prednisone for ≥ 12 weeks.",
                        "criterion": "prior ARPI treatment (excluding abiraterone acetate with prednisone) for CRPC",
                        "requirement": {
                            "requirement_type": "disease setting",
                            "expected_value": [
                                "metastatic CRPC",
                                "non-metastatic CRPC"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment with abiraterone acetate with prednisone in the mHSPC or locally advanced setting is not exclusionary.",
                        "criterion": "prior abiraterone acetate with prednisone treatment in mHSPC or locally advanced setting",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment with abiraterone acetate with prednisone in the mHSPC or locally advanced setting is not exclusionary.",
                        "criterion": "prior abiraterone acetate with prednisone treatment in mHSPC or locally advanced setting",
                        "requirement": {
                            "requirement_type": "treatment agent",
                            "expected_value": "abiraterone acetate with prednisone"
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment with abiraterone acetate with prednisone in the mHSPC or locally advanced setting is not exclusionary.",
                        "criterion": "prior abiraterone acetate with prednisone treatment in mHSPC or locally advanced setting",
                        "requirement": {
                            "requirement_type": "disease setting",
                            "expected_value": [
                                "mHSPC",
                                "locally advanced"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment with abiraterone acetate with prednisone in the mHSPC or locally advanced setting is not exclusionary.",
                        "criterion": "prior abiraterone acetate with prednisone treatment in mHSPC or locally advanced setting",
                        "requirement": {
                            "requirement_type": "exclusionary status",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}